Lombard Medical is focused on the development, manufacturing and commercialisation of innovative endovascular aortic repair (EVAR) devices such as abdominal and thoracic aortic aneurysms (AAA & TAC respectively). The lead product, 'Aorfix' for AAA is a synthetic aortic abdominal bifurcated stent-graft, marketed in Europe through direct sales in the UK and in Germany and through a network of local distributors supported by clinical specialists from Lombard Medical in the rest of Continental Europe. In the US 'Aorfix' is in the final stages of the regulatory approval, having filed five of the six Pre-Market Approval (PMA) filings and having received approval for the first three PMA modules. Aorfix has been designed to also address complex and tortuous aneurysmal or iliac anatomy including those with high-angle-neck angulations (up-to 90degrees), that are normally referred to open surgery as they are not currently covered by marketed devices, allowing Lombard Medical to cater for a larger number of aneurysms.
WHY CHOOSE ED
"Many thanks to @equity_research for a superb Investor Forum. $BMK.L , $VLG.L & $VP.L all interesting companies. I recommend these events. "
"We cannot thank you enough for opening our eyes to private investors."
"MHP believes commissioned research is an important part of the toolkit to attract new investors and improve liquidity. We rate ED's analysts and research very highly as one of the leading providers in this space."
"One of the biggest problems private investors have, is getting access to broker research. It’s basically impossible for many investors. Therefore I feel some commissioned research is really important and a good investment for companies. In my experience ED are far more proactive than other firms in this space."
Blogger and Stockopedia Contributor
"There is a need now, more than ever before, for real insight and clarity to be brought to company messages for investors….I would strongly recommend Equity Development to the management of any company."
Small Cap Equity Salesman
"From early days as a private company through to being established on AIM, I have always been able to rely on ED for wise counsel, perceptive research and introductions to new, supportive shareholders."
"I would like to thank and congratulate you, particularly Liz, on your note. It’s short, sharp, pulls out the key issues and I believe will be a valuable asset for our retail outreach."
"The team at ED consistently produce high quality research and highlight profitable investment opportunities, an invaluable tool for small cap investors in this under researched space."
"I thoroughly enjoyed the investor evening again, and as before its good that you get such an interested audience who engage and ask us all decent questions."